These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24324095)

  • 1. Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid.
    Chao TC; Chen DR; Chao TY; Chen SC; Yeh DC; Wang HC; Huang WT; Rau KM; Chang KJ; Yang TL; Lee KD; Tai CJ; Tseng LM; Hou MF
    Anticancer Res; 2013 Dec; 33(12):5543-7. PubMed ID: 24324095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
    Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF
    In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.
    Walker MS; Miller PJ; Namjoshi M; Houts AC; Stepanski EJ; Schwartzberg LS
    J Med Econ; 2013; 16(1):179-89. PubMed ID: 23043593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
    Weinfurt KP; Castel LD; Li Y; Timbie JW; Glendenning GA; Schulman KA
    Med Care; 2004 Feb; 42(2):164-75. PubMed ID: 14734954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
    Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid in lung cancer with bone metastases: a review.
    Isla D; Afonso R; Bosch-Barrera J; Martínez N
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):421-6. PubMed ID: 23560837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
    Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
    Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.
    Chiang PH; Wang HC; Lai YL; Chen SC; Yen-Hwa W; Kok CK; Ou YC; Huang JS; Huang TC; Chao TY
    J Cancer Res Ther; 2013; 9(4):653-9. PubMed ID: 24518712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.
    Montella L; Addeo R; Palmieri G; Caraglia M; Cennamo G; Vincenzi B; Guarrasi R; Mamone R; Faiola V; Frega N; Capasso E; Maiorino L; Leopardo D; Pizza C; Montesarchio V; Del Prete S
    Cancer Chemother Pharmacol; 2010 May; 65(6):1137-43. PubMed ID: 19760218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.